| Revenue Growth | Subscription revenue $24.9M down 23%; AMG visit revenue $28.9M up 9%. |
|---|---|
| Mgmt Confidence | High confidence in Q4 cash flow breakeven and multi-year growth trajectory. |
| Demand Visibility | Pipeline is a multiple of last year; triple-digit growth in opportunities. |
| Margin Trends | Gross margin 51% down 180bps; adjusted EBITDA loss improved $9.1M. |
| Op. Leverage | Operating expenses fell 31% to $45.4M; 82.6% of revenue vs 98.3%. |
| Pricing Power | Revenue per visit increased $5 to $76; renewals higher than budgeted. |
| Vol vs Price | VPC visits up 57%; platform visits down 19% due to churn. |
| Segment Growth | Virtual Primary Care up 57%; subscription revenue 53% of total mix. |
| New Clients | Elevance Health renewed for 3 years; DHA contract extension August 2025. |
| Capex & Debt | $179M cash and investments with zero debt; $3.1M quarterly burn. |
| Regulatory | CMS permanent telehealth flexibility and new reimbursement codes provide direct tailwinds. |
| Commentary | Shifting from 'AI features' to being the infrastructure layer for agentic AI. |
| New Launches | Unified Amwell platform; automated behavioral health programs for military/NHS. |
Growth
Q1 revenue fell 18% to $54.9M; AMG visit revenue grew 9% to $28.9M.
Outlook
Targeting positive cash flow in Q4 2026; full-year revenue guided at $195M-$205M.
Risks
Management pivoted to qualitative confidence when asked for specific dollar values of DHA expansion opportunities.
The company's earnings call, NYSE: AMWL, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
American Well Corp: key numbers
- Share price
- $11.34Close, Nov 16
- Sector
- Trade & Services
- Industry
- Services-Business Services, NECSIC 7389
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from American Well Corp
All →American Well Q3 2026 Results: Net Loss of $11.4M, Loss Narrows
For the quarter ended September 30, 2026, American Well reported revenue of $49.0 million, a decrease from $56.3 million in the prior year period. The company significantly narrowed its net loss to $11.0 million compared to $31.9 million in 2025, driven by substantial reductions in research and development and general and administrative expenses.
- Key figure
- Net loss $11.4M
American Well Financial Results
American Well Corp (Amwell) reported Q3 2026 total revenue of $49.0 million, exceeding its previous guidance, and a net loss of $11.0 million. The company raised its full-year 2026 revenue outlook to a range of $204-$206 million and reiterated its goal to achieve positive cash flow from operations in the fourth quarter of 2026.
- Term
- Q3 2026
“Health plans and employers want engagement, outcomes and proof, and Amwell’s single platform is built to deliver all three. Across six focus areas that all run on one platform, we are activating more members, simplifying their experience and deepening their relationship with clinicians, giving customers choice without the sprawl, demonstrating outcomes, and using a common data structure to show what works. We expect to generate positive cash flow from operations in the fourth quarter, and we believe we are well positioned to be the trusted platform where AI-powered care runs.”
Dr. Ido Schoenberg, Chairman and CEO of Amwell
American Well President, International Phyllis Gotlib Sells $86.8K of Stock
Phyllis Gotlib, President, International, sold 6,677 shares of American Well Corp at $13.00 a share, worth $86.8K in total on Oct 1, 2026. Shares held after the trade: 142,504 (-4.5%).
- Value
- $86.8K
- Shares
- 6,677
- Price
- $13.00
- Role
- President, International
- Holding change
- -4.5%
- Trade date
- Oct 1, 2026
American Well CFO Mark Hirschhorn Sells $55.7K of Stock
Mark Hirschhorn, CFO, sold 4,282 shares of American Well Corp at $13.00 a share, worth $55.7K in total on Oct 1, 2026. Shares held after the trade: 223,906 (-1.9%).
- Value
- $55.7K
- Shares
- 4,282
- Price
- $13.00
- Role
- CFO
- Holding change
- -1.9%
- Trade date
- Oct 1, 2026
American Well Chief Product & Tech. Officer Dmitry Zamansky Sells $110K of Stock
Dmitry Zamansky, Chief Product & Tech. Officer, sold 8,442 shares of American Well Corp at $13.00 a share, worth $110K in total on Oct 1, 2026. Shares held after the trade: 224,178 (-3.6%).
- Value
- $110K
- Shares
- 8,442
- Price
- $13.00
- Role
- Chief Product & Tech. Officer
- Holding change
- -3.6%
- Trade date
- Oct 1, 2026